Efficacy of different regimens and prognostic factors in patients with first relapsed multiple myeloma treated after front-line bortezomib,cyclophosphamide,and dexamethasone

被引：0
|
作者：
陈苗
机构：
[1] Dept Hematol
[2] PUMC&CAMS
来源：
China Medical Abstracts(Internal Medicine) | 2024年 / 41卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R733.3 [骨髓肿瘤];
学科分类号：
摘要：
Objective To.analyze the efficacy of second-line regimens and prognostic factors in patients with firstrelapsed multiple myeloma (MM) treated with bortezomib,cyclophosphamide,and dexamethasone(BCD).Methods Clinical data were collected in firstrelapsed MM patients after BCD treatment from three tertiary hospitals in north China from July 2009 to October 2022.
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [1] Clinical Efficacy of a Bortezomib, Cyclophosphamide and Dexamethasone Compared with Bortezomib, Cyclophosphamide, Thalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Ahn, Jae-Sook
    Yang, Deok-Hwan
    Moon, Joon Ho
    Sohn, Sang Kyun
    Jung, Sung-Hoon
    Bae, Soo-Young
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BLOOD, 2011, 118 (21) : 815 - 815
  • [2] Early mortality and treatment discontinuation in multiple myeloma patients treated in front-line with bortezomib, lenalidomide and dexamethasone (VRD)
    Oriol, Albert
    Canelo-Vilaseca, Marta
    Sanchez, Carla
    Abril, Laura
    Escoda, Lourdes
    Ibarra, Gladys
    Abella, Eugenia
    Motllo, Cristina
    Gonzalez-Montes, Yolanda
    Granada, Isabel
    Cabezudo, Elena
    Senin, Alicia
    Ben, Randa
    Jurado, Rebeca
    de Jaureguizar, Alejandro
    Ribera, Josep-Maria
    Sarra, Josep
    Sancho, Juan-Manuel
    Sureda, Anna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S146 - S147
  • [3] Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse
    Montefusco, Vittorio
    Corso, Alessandro
    Galli, Monica
    Ardoino, Ilaria
    Pezzatti, Sara
    Carniti, Cristina
    Patriarca, Francesca
    Gherlinzoni, Filippo
    Zambello, Renato
    Sammassimo, Simona
    Marcatti, Magda
    Nozza, Andrea
    Crippa, Claudia
    Cafro, Anna Maria
    Baldini, Luca
    Corradini, Paolo
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (06) : 907 - 917
  • [4] Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma
    Jakubowiak, A. J.
    Hofmeister, C.
    Campagnaro, E.
    Kendall, T.
    Zimmerman, T.
    Schlossman, R.
    Reece, D.
    Lonial, S.
    Hari, M.
    Hector-Word, Z.
    Griffith, K.
    Tendler, C.
    Esseltine, D. L.
    Bock, T.
    Kaminski, M.
    Dollard, A.
    Kelley, S.
    Anderson, K. C.
    Richardson, P. G.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S45 - S46
  • [5] PAD (PS-341/bortezomib, adriamycin and dexamethasone) as front-line therapy for untreated patients with multiple myeloma
    Popat, R
    Oakervee, H
    Foot, N
    Curry, N
    Morris, C
    Drake, M
    Agrawal, S
    Smith, P
    Schenkein, D
    Esseltine, D
    Cavenagh, JD
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 22 - 22
  • [6] EFFICACY OF THE COMBINATION THERAPY OF LIPOSOMAL ADRYAMICIN, BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (ABCD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
    Romano, A.
    Chiarenza, A.
    Gorgone, A.
    Schinocca, L.
    Uccello, G.
    Cavalli, M.
    Fiumara, P.
    Motta, G.
    Palumbo, G.
    Di Raimondo, F.
    HAEMATOLOGICA, 2012, 97 : 607 - 607
  • [7] Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
    Kristian T. Andersen
    Maja Hinge
    Agoston Gyula Szabo
    Erik Segel
    Tina Ormstrup
    Paw C. Holdgaard
    Niels Pallisgaard
    Gitte Kerndrup
    Torben Plesner
    Clinical Hematology International, 2020, 2 (1) : 35 - 39
  • [8] BORTEZOMIB PLUS DEXAMETHASONE IN COMBINATION WITH MELPHALAN OR CYCLOPHOSPHAMIDE IN THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Tsirigotis, P.
    Girkas, K. G.
    Giannopoulou, V.
    Chondropoulos, S.
    Ioannidou, E.
    Papaxoinis, G.
    Pappa, V.
    Vasilatou, D.
    Dimoula, K.
    Kapodistrias, N.
    Papageorgiou, E.
    Economopoulos, T.
    Dervenoulas, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 436 - 436
  • [9] CLINICAL EFFICACY OF VELCADE (BORTEZOMIB) AND DEXAMETHASONE THERAPY IN PATIENTS WITH REFRACTORY OR RELAPSED MULTIPLE MYELOMA
    Ionita, I.
    Cheveresan, M.
    Calamar, D.
    Ionita, C.
    Oros, D.
    Ionita, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 627 - 628
  • [10] Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial
    Manasanch, Elisabet E.
    Shah, Jatin J.
    Lee, Hans C.
    Weber, Donna M.
    Thomas, Sheeba K.
    Amini, Behrang
    Feng, Lei
    Berkova, Zuzana
    Hildebrandt, Michelle
    Orlowski, Robert Z.
    LANCET HAEMATOLOGY, 2018, 5 (12): : E628 - E640
12345